2026 Q2 - tulosraportti
42 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,17%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 2 000 | - | - | ||
| 500 | - | - | ||
| 561 | - | - | ||
| 4 439 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 min sittenSurely we'll go under 270 today 🤔, it's well on its way ⬇️⬇️⬇️
Well Per Snotskovl, it's been at the same level for the last couple of hours🙃 why do you have to scare a bit?👹
·16 min sittenWhat's happening Novo?! :-(
They just made an AI agreement (they had two already). Now I assume it will be three times as good, so it looks like a bright future for Novo.
·16 min sittenShould one buy something now to lower one's GAK or should one wait a day or two for it?
One should ONLY buy into stocks that are going down, PROVIDED the fall is not due to the company bleeding, but is caught in an unbearable downturn due to external challenges. Fair winds, but consider whether you should let others' opinions be the basis for YOUR investments.....good luck.
·49 min sittenNow Big A must step up and correct Mads Zink from danske Bank who claims that Americans are selling off Novo under high volume - That simply cannot be right, USA is buying heavily under low volume, if I have understood it correctly.Where and how can the postulate that "Americans are selling" be observed....hmmm - the price falls after the opening: yes - Americans are selling massively...this cannot really be concluded as volume and price show what is happening with the stock, but not WHO is selling solely based on price and volume. - large volume on the fall..that's the question. MarketWatch shows 171,530 shares around 9:30. AI states that the 65-day average is 11.42 million. The early trading must be thin.... There is selling pressure in the USA. Market data shows about 3.9 million shares traded against an average of approx. 11.45 million (AI information). Conclusion: USA is selling Novo down (I doubt if it's the market generally within the industry). But it probably cannot be proven that it is a massive sale on unusually high volume. The market is mysterious....or is it?
·1 t sittenI went "all in" in the final sprint. 36 years in stocks and have never done it before, but I have faith and an ACB of 275. Here is AI (pro model) response about Capital Markets Day .... : Novo Nordisk – exciting pipeline update before EASD Novo Nordisk has announced that the company will present a total of 44 abstracts at the diabetes congress EASD in Milan from September 28 to October 2. The interesting thing is that the presentations are not only about diabetes and weight loss, but about the entire cardiometabolic portfolio: obesity, type 2 diabetes, cardiovascular disease, kidney disease, and liver disease. For me, there are especially three things to keep an eye on: 1. Wegovy as a tablet Novo will present real-world data for Wegovy in tablet form. It will be important to see how the treatment works in practice outside of clinical trials. If patients achieve good results, and the pill can also attract patients who do not want injections, it could become an important growth driver. 2. CagriSema New data will be released on, among other things, appetite, eating behavior, body composition, and bone health. The market already has high expectations for CagriSema, so Novo must show that the product not only delivers weight loss but also has a strong overall clinical profile. 3. Zenagamtide/amycretin In my opinion, this is perhaps the most interesting long-term product in the pipeline. Novo is trying to build the next generation of treatments after Wegovy and CagriSema, and more data here could strengthen the market's belief in growth well into the 2030s. New results for Wegovy 7.2 mg and Ozempic 2.0 mg will also be released, so EASD can give the market a fairly broad picture of how strong Novo Nordisk's pipeline actually is. The timing is interesting because Novo will first hold its Capital Markets Day on September 21 and then EASD the week after. This gives the company two opportunities in a short time to change the market's narrative from: "Novo has lost momentum" to: "Novo still has a strong pipeline and several new growth drivers on the way." If Novo delivers strong results, especially for oral Wegovy, CagriSema, and zenagamtide, September could become an important month for the stock's long-term investment case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |
2026 Q2 - tulosraportti
42 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,17%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenSurely we'll go under 270 today 🤔, it's well on its way ⬇️⬇️⬇️Well Per Snotskovl, it's been at the same level for the last couple of hours🙃 why do you have to scare a bit?👹
- ·16 min sittenWhat's happening Novo?! :-(They just made an AI agreement (they had two already). Now I assume it will be three times as good, so it looks like a bright future for Novo.
- ·16 min sittenShould one buy something now to lower one's GAK or should one wait a day or two for it?One should ONLY buy into stocks that are going down, PROVIDED the fall is not due to the company bleeding, but is caught in an unbearable downturn due to external challenges. Fair winds, but consider whether you should let others' opinions be the basis for YOUR investments.....good luck.
- ·49 min sittenNow Big A must step up and correct Mads Zink from danske Bank who claims that Americans are selling off Novo under high volume - That simply cannot be right, USA is buying heavily under low volume, if I have understood it correctly.Where and how can the postulate that "Americans are selling" be observed....hmmm - the price falls after the opening: yes - Americans are selling massively...this cannot really be concluded as volume and price show what is happening with the stock, but not WHO is selling solely based on price and volume. - large volume on the fall..that's the question. MarketWatch shows 171,530 shares around 9:30. AI states that the 65-day average is 11.42 million. The early trading must be thin.... There is selling pressure in the USA. Market data shows about 3.9 million shares traded against an average of approx. 11.45 million (AI information). Conclusion: USA is selling Novo down (I doubt if it's the market generally within the industry). But it probably cannot be proven that it is a massive sale on unusually high volume. The market is mysterious....or is it?
- ·1 t sittenI went "all in" in the final sprint. 36 years in stocks and have never done it before, but I have faith and an ACB of 275. Here is AI (pro model) response about Capital Markets Day .... : Novo Nordisk – exciting pipeline update before EASD Novo Nordisk has announced that the company will present a total of 44 abstracts at the diabetes congress EASD in Milan from September 28 to October 2. The interesting thing is that the presentations are not only about diabetes and weight loss, but about the entire cardiometabolic portfolio: obesity, type 2 diabetes, cardiovascular disease, kidney disease, and liver disease. For me, there are especially three things to keep an eye on: 1. Wegovy as a tablet Novo will present real-world data for Wegovy in tablet form. It will be important to see how the treatment works in practice outside of clinical trials. If patients achieve good results, and the pill can also attract patients who do not want injections, it could become an important growth driver. 2. CagriSema New data will be released on, among other things, appetite, eating behavior, body composition, and bone health. The market already has high expectations for CagriSema, so Novo must show that the product not only delivers weight loss but also has a strong overall clinical profile. 3. Zenagamtide/amycretin In my opinion, this is perhaps the most interesting long-term product in the pipeline. Novo is trying to build the next generation of treatments after Wegovy and CagriSema, and more data here could strengthen the market's belief in growth well into the 2030s. New results for Wegovy 7.2 mg and Ozempic 2.0 mg will also be released, so EASD can give the market a fairly broad picture of how strong Novo Nordisk's pipeline actually is. The timing is interesting because Novo will first hold its Capital Markets Day on September 21 and then EASD the week after. This gives the company two opportunities in a short time to change the market's narrative from: "Novo has lost momentum" to: "Novo still has a strong pipeline and several new growth drivers on the way." If Novo delivers strong results, especially for oral Wegovy, CagriSema, and zenagamtide, September could become an important month for the stock's long-term investment case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 2 000 | - | - | ||
| 500 | - | - | ||
| 561 | - | - | ||
| 4 439 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |
2026 Q2 - tulosraportti
42 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
3,75 DKK/osake
Viimeisin osinko
4,17%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 min sittenSurely we'll go under 270 today 🤔, it's well on its way ⬇️⬇️⬇️Well Per Snotskovl, it's been at the same level for the last couple of hours🙃 why do you have to scare a bit?👹
- ·16 min sittenWhat's happening Novo?! :-(They just made an AI agreement (they had two already). Now I assume it will be three times as good, so it looks like a bright future for Novo.
- ·16 min sittenShould one buy something now to lower one's GAK or should one wait a day or two for it?One should ONLY buy into stocks that are going down, PROVIDED the fall is not due to the company bleeding, but is caught in an unbearable downturn due to external challenges. Fair winds, but consider whether you should let others' opinions be the basis for YOUR investments.....good luck.
- ·49 min sittenNow Big A must step up and correct Mads Zink from danske Bank who claims that Americans are selling off Novo under high volume - That simply cannot be right, USA is buying heavily under low volume, if I have understood it correctly.Where and how can the postulate that "Americans are selling" be observed....hmmm - the price falls after the opening: yes - Americans are selling massively...this cannot really be concluded as volume and price show what is happening with the stock, but not WHO is selling solely based on price and volume. - large volume on the fall..that's the question. MarketWatch shows 171,530 shares around 9:30. AI states that the 65-day average is 11.42 million. The early trading must be thin.... There is selling pressure in the USA. Market data shows about 3.9 million shares traded against an average of approx. 11.45 million (AI information). Conclusion: USA is selling Novo down (I doubt if it's the market generally within the industry). But it probably cannot be proven that it is a massive sale on unusually high volume. The market is mysterious....or is it?
- ·1 t sittenI went "all in" in the final sprint. 36 years in stocks and have never done it before, but I have faith and an ACB of 275. Here is AI (pro model) response about Capital Markets Day .... : Novo Nordisk – exciting pipeline update before EASD Novo Nordisk has announced that the company will present a total of 44 abstracts at the diabetes congress EASD in Milan from September 28 to October 2. The interesting thing is that the presentations are not only about diabetes and weight loss, but about the entire cardiometabolic portfolio: obesity, type 2 diabetes, cardiovascular disease, kidney disease, and liver disease. For me, there are especially three things to keep an eye on: 1. Wegovy as a tablet Novo will present real-world data for Wegovy in tablet form. It will be important to see how the treatment works in practice outside of clinical trials. If patients achieve good results, and the pill can also attract patients who do not want injections, it could become an important growth driver. 2. CagriSema New data will be released on, among other things, appetite, eating behavior, body composition, and bone health. The market already has high expectations for CagriSema, so Novo must show that the product not only delivers weight loss but also has a strong overall clinical profile. 3. Zenagamtide/amycretin In my opinion, this is perhaps the most interesting long-term product in the pipeline. Novo is trying to build the next generation of treatments after Wegovy and CagriSema, and more data here could strengthen the market's belief in growth well into the 2030s. New results for Wegovy 7.2 mg and Ozempic 2.0 mg will also be released, so EASD can give the market a fairly broad picture of how strong Novo Nordisk's pipeline actually is. The timing is interesting because Novo will first hold its Capital Markets Day on September 21 and then EASD the week after. This gives the company two opportunities in a short time to change the market's narrative from: "Novo has lost momentum" to: "Novo still has a strong pipeline and several new growth drivers on the way." If Novo delivers strong results, especially for oral Wegovy, CagriSema, and zenagamtide, September could become an important month for the stock's long-term investment case.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | - | - | ||
| 2 000 | - | - | ||
| 500 | - | - | ||
| 561 | - | - | ||
| 4 439 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 4 157 196 | 4 157 196 | 0 | 0 |